Developability Assessment for De Novo Designed Binders
Generative design made binder sequences cheap to produce, but developability assessment for de novo designed binders did not keep up, so a design can reach DNA synthesis without a liability screen having been run at all. This guide is the screen.
Download the free guide
Enter your details to get instant access.
Written for the bench, not for a regulatory filing
A different bar than a clinical antibody
Which developability properties actually matter at design stage, and which belong to a formulation question you are not asking yet.
The liabilities that kill designs
Glycosylation sequons, unpaired cysteines, aggregation-prone stretches, charge and pI extremes, humanness, polyreactivity, deamidation and oxidation. For each: what it is, why designs get it, the sequence signal, and what to do.
Where sequence alone runs out
Exposure, structural context and interface proximity are what turn a sequence pattern into a finding. What spatial aggregation propensity and surface patch analysis add, and what they cost.
A triage workflow before synthesis
A pass over a design set that ends in three buckets: fix and re-run, discard, or carry with a watch and a matching assay.
Using published thresholds honestly
Published cutoffs are population statistics about clinical-stage antibodies. Four ways that inference breaks on a designed binder, and how to use the numbers anyway.
Open-source tooling and licences
A table of the tools worth running, each with the licence its own repository reports, and two projects that are not licensed for commercial use.
Want the screen run for you?
We run de novo binder campaigns, and developability checks are part of how we decide what gets synthesised. Tell us about your target and we will tell you which program fits.
Start a project →